Navigation Links
NIH clinical trial begins for treatment of rare, fatal neurological disorder
Date:1/23/2013

A clinical trial to evaluate a drug candidate called cyclodextrin as a possible treatment for Niemann-Pick disease type C1 (NPC), a rare and fatal genetic disease, will start today, researchers announced. Scientists from the NIH's National Center for Advancing Translational Sciences (NCATS) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) will conduct the clinical trial at the NIH Clinical Center. Reaching this trial stage required collaboration among government, industry, patient advocacy groups and academic researchers.

No therapies approved by the U.S Food and Drug Administration are available to treat NPC. The disease is characterized by the inability of cells to metabolize and dispose of cholesterol and lipids. It causes excessive amounts of cholesterol to accumulate within the liver, spleen and brain. NPC leads to progressive impairment of motor and intellectual function in early childhood. In childhood onset cases, life expectancy does not normally exceed a patient's teenage years.

"A crucial part of the NCATS mission is to collaborate within and beyond the NIH on projects to improve and accelerate the translational research process and deliver tangible improvements in human health," said NCATS Director Christopher P. Austin, M.D. "The cyclodextrin project is an important step in the development of both a potential treatment for a devastating disease that ravages the bodies and minds of its victims and a more efficient way to do translational projects."

In 2009, the NIH Therapeutics for Rare and Neglected Diseases (TRND) program, which is now led by NCATS, selected NPC cyclodextrin as one of its initial pilot projects to repurpose cyclodextrin from its conventional use as an ingredient in other drugs to a therapeutic for this rare disorder. TRND researchers work with project collaborators to conduct preclinical studies advancing potential treatments for rare and neglected diseases to human clinical trials.

TRND supported animal toxicology studies to evaluate the safety of cyclodextrin and all necessary regulatory efforts and also supported the development of an NPC biomarker. The biomarker test detects in the blood a modified cholesterol molecule specific to neuronal cells in the brain that would increase as a result of treatment with cyclodextrin.

TRND researchers and collaborators submitted the data in an Investigational New Drug application, filed Nov. 14, 2012, that the Food and Drug Administration (FDA) has now agreed is sufficient to start a Phase I clinical trial.

"The multidisciplinary nature of this collaboration establishes a generalizable model that can be used in the pursuit of treatment candidates for rare and neglected diseases," said John McKew, Ph.D., acting director of the NCATS Division of Pre-Clinical Innovation, chief of the Therapeutic Development Branch and director of TRND. "In addition, the FDA was instrumental in helping our team move this project into human clinical trials."

The NPC Phase I clinical trial will test multiple doses of cyclodextrin in nine patients. Forbes Porter, M.D., Ph.D., senior investigator and NICHD clinical director, and Nuria Carrillo, M.D., TRND staff physician, will conduct the trial. Dr. Porter also is conducting a natural history study of NPC to collect health information from patients to understand how the disease develops. The natural history study is critical to understanding the clinical significance of a treatment for NPC patients.

"Initiation of this clinical trial is the culmination of two decades of basic and clinical research to understand and develop therapies for NPC," said Porter. "The efforts of the collaborators who make up the TRND NPC team have greatly accelerated translating cyclodextrin from the laboratory to the clinic."

The goal of the Phase I clinical trial is to determine a safe dose of cyclodextrin that will support an expanded Phase II trial to begin to evaluate the effectiveness of the drug. The team already is in the initial stages of collaborating with the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT), which is administered by the NIH's National Institute of Neurological Disorders and Stroke, to plan a Phase II multicenter trial.

The NPC cyclodextrin project was made possible by a collaborative approach that also included in addition to NCATS, NICHD, National Institute of Neurological Disorders and Stroke (NINDS) and the FDA the NIH's National Human Genome Research Institute; Johnson and Johnson Pharmaceutical Research & Development; Washington University in St. Louis School of Medicine; Albert Einstein School of Medicine, New York City, and University of Pennsylvania, Philadelphia. A number of family support groups have made significant contributions as well that have led to the launch of the clinical trial through the funding of NPC research and patient support. They include the Ara Parshegian Medical Research Foundation, the International Niemann Pick Disease Alliance, the National Niemann Pick Disease Foundation, and Support Of Accelerated Research for Niemann Pick Type C.

The NPC clinical trial is the fourth TRND project to advance to human clinical trials in the last 15 months. The three other clinical trials are evaluating treatments for sickle cell disease, chronic lymphocytic leukemia and hereditary inclusion body myopathy. TRND has a portfolio of 14 projects, which focus on rare and neglected tropical diseases.


'/>"/>

Contact: NCATS Office of Communications
info@ncats.nih.gov
301-435-0888
NIH/National Center for Advancing Translational Sciences (NCATS)
Source:Eurekalert

Related medicine news :

1. ASH international clinical collaboration replicates high cure rate of APL in developing countries
2. Life Support Technologies Group Appoints Edward Golembe, MD as Co-Clinical Director
3. Life Support Technologies Group Appoints Scott Gorenstein, MD as Co-Clinical Director
4. Declining access to electroconvulsive therapy: A clinical choice or an economic one?
5. Regenerative medicine: Clinical trials launched for the treatment of delayed union fractures
6. Cancer Genome Institute at Fox Chase among first to offer clinical blueprint of cancer genes
7. When will genomic research translate into clinical care -- and at what cost?
8. Clinical Nutrition, 2nd Edition
9. BioPharm Systems to Host Webinar on Using iHelp in Oracle’s Siebel Clinical Trial Management System
10. Sozo Nutritionals Announces Release of Svetol® Based Natural Weight Loss Product Backed By Several Clinical Studies Showing Remarkable Weight Loss Benefits
11. APS announces inaugural issue of new journal, Clinical Psychological Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... , ... In its just released 2018 Edition, The Best Lawyers in America ... third consecutive year that Hardiman and Mills have been honored and the seventh year ... Health Care Law while Mills was recognized in the Administrative and Regulatory Law category. ...
(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article on NextShark ... surgery, largely influenced by the growing popularity of “pretty boys” in both K-Pop and ... standards of male appearance are changing not only in the Asian nation, where plastic ...
(Date:8/17/2017)... Valley, PA (PRWEB) , ... August 17, 2017 , ... ... Azzur Labs Ranking at No. 132 with Three-Year Sales Growth of 3,004.8% , NEW ... its 36th annual Inc. 5000, the most prestigious ranking of the nation's fastest-growing private ...
(Date:8/17/2017)... ... August 17, 2017 , ... Centrifugation is more than just ... laboratory that we can no longer do without. And just like a car, there ... device. , In this webinar, attendees will learn about the most important safety aspects ...
(Date:8/16/2017)... ... 2017 , ... Summer days spent with family are priceless. Since August is ... for enjoying the season of sunshine. Add trying something new to this summer’s bucket ... in on the fun. , Try Something New , Choose an ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator of ... to be in the beginning stages of an IPO. ... epilepsy medications with the average cost of a prescription epilepsy drug being ... AXIUM ... Another staggering figure is the fact that ...
(Date:8/14/2017)... PETACH TIKVAH, Israel , Aug. 15, ... leading developer of adult stem cell technologies for neurodegenerative ... June 30, 2017. ... our pivotal Phase 3 trial to investigate NurOwn ® ... and Chief Executive Officer of BrainStorm. "We have agreements ...
(Date:8/8/2017)... -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused ... for the second quarter ended June 30, 2017. ... and to date: ... Company,s lead project, BL-8040: Announced plans ... novel stem cell mobilization treatment for autologous bone-marrow transplantation ...
Breaking Medicine Technology: